Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

被引：0
|
作者：
Hajime Abe
Tsuyoshi Mori
Yuki Kawai
Hirotomi Cho
Yoshihiro Kubota
Tomoko Umeda
Yoshimasa Kurumi
Tohru Tani
机构：
[1] Shiga University of Medical Science Hospital,Division of Breast and General Surgery
[2] Shiga University of Medical Science,Department of Comprehensive Surgery
[3] Shiga University of Medical Science,Department of Surgery
来源：
International Journal of Clinical Oncology | 2013年 / 18卷
关键词：
Adjuvant chemotherapy; Docetaxel; Early breast cancer; Feasibility; FEC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：487 / 491
页数：4
相关论文
共 50 条
  • [21] Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
    Mirzaei, Hamid Reza
    Rasekh, Parisa Sabet
    Nasrollahi, Fatemeh
    Rasekh, Parto Sabet
    Tirabad, Zahra Akbari
    RezaMoein, Hamid
    Pour, Taban Ghaffari
    Hajian, Parastoo
    [J]. INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [22] Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide
    Sun, Weiling
    Li, Chunhong
    Liu, Meiyan
    Liu, Wei
    Yang, Chunyu
    Cai, Li
    [J]. ONCOLOGY LETTERS, 2016, 11 (03) : 2320 - 2326
  • [23] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    [J]. TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
  • [24] Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
    Heller, W.
    Mazhar, D.
    Ward, R.
    Sinnett, H. D.
    Lowdell, C.
    Phillips, R.
    Shousha, S.
    Fayaz, A.
    Palmieri, C.
    Coombes, R. C.
    [J]. ONCOLOGY REPORTS, 2007, 17 (01) : 253 - 259
  • [25] Feasibility study of adjuvant fluorouracil/epirubicin/cyclophosphamide (FEC 100) followed by triweekly docetaxel (D) plus trastuzumab (H) in HER2/neu positive early breast cancer
    Tanaka, M.
    Anan, K.
    Umeda, S.
    Yamaguchi, M.
    Sasaki, H.
    Rai, Y.
    Ohno, S.
    Toh, U.
    Tamura, K.
    Mitsuyama, S.
    [J]. BREAST, 2011, 20 : S66 - S67
  • [26] A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer
    Lindman, H.
    Andersson, M.
    Edlund, P.
    Bjerre, K. D.
    Hatschek, T.
    Mouridsen, H. T.
    Anderson, H.
    Ejlertsen, B.
    Moller, S.
    Lidbrink, E.
    Kamby, C.
    Ahlgren, J.
    Bergh, J.
    Blomqvist, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
    Joensuu, Heikki
    Bono, Petri
    Kataja, Vesa
    Alanko, Tuomo
    Kokko, Riitta
    Asola, Raija
    Utriainen, Tapio
    Turpeenniemi-Hujanen, Taina
    Jyrkkio, Sirkku
    Moykkynen, Kari
    Helle, Leena
    Ingalsuo, Seija
    Pajunen, Marjo
    Huusko, Mauri
    Salminen, Tapio
    Auvinen, Paivi
    Leinonen, Hannu
    Leinonen, Mika
    Isola, Jorma
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5685 - 5692
  • [28] Feasibility study of fluorouracil/epirubicin/cyclophosphamicle (FEC75) followed by docetaxel (DOC) as adjuvant chemotherapy in Japanese patients with node positive breast cancer
    Rai, Y.
    Tanaka, M.
    Mitsuyama, M.
    Uga, T.
    Tanaka, S.
    Nanba, K.
    Furusawa, H.
    Murata, K.
    Nishimura, R.
    Oikawa, T.
    Kamada, Y.
    Maeda, S.
    Maeda, J.
    Honjyo, S.
    Iwase, H.
    Yamamoto, Y.
    Masuno, K.
    Shibuta, K.
    Kai, Y.
    Taniguchi, H.
    Yahara, T.
    Yokoyama, G.
    Yoshinaga, Y.
    Umeda, S.
    Hisamatsu, K.
    Tamura, K.
    [J]. BREAST, 2009, 18 : S54 - S54
  • [29] Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
    Vulsteke, C.
    Pfeil, A. M.
    Schwenkglenks, M.
    Pettengell, R.
    Szucs, T. D.
    Lambrechts, D.
    Peeters, M.
    van Dam, P.
    Dieudonne, A. S.
    Hatse, S.
    Neven, P.
    Paridaens, R.
    Wildiers, H.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (03) : 557 - 570
  • [30] Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
    C. Vulsteke
    A. M. Pfeil
    M. Schwenkglenks
    R. Pettengell
    T. D. Szucs
    D. Lambrechts
    M. Peeters
    P. van Dam
    A. S. Dieudonné
    S. Hatse
    P. Neven
    R. Paridaens
    H. Wildiers
    [J]. Breast Cancer Research and Treatment, 2014, 147 : 557 - 570
12345